这就是Infliximab
1Department of Pediatrics, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul 03181, South Korea.
在儿科克罗恩氏病 (CD) 治疗中,在因弗力西马布 (IFX) 和阿达利穆马布 (ADL) 之间做出选择需要仔细考虑. 药理动力学建议IFX用于高炎症和ADL用于缓解维持,影响治疗决策.
科学领域:
- 儿科胃肠病学 儿科胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 生物药物用于克罗恩病 (CD).
- 因弗利西马布 (IFX) 和阿达利穆马布 (ADL) 是美国食品和药物管理局 (FDA) 批准用于儿科CD的唯一生物药物.
- 对于儿科CD中的生物药物,有限的对比试验存在,需要从成人数据中推断.
研究的目的:
- 为在儿科CD中选择抗瘤亡因子 (TNF) 治疗提供实用见解.
- 根据现有数据,比较因弗利西马布 (IFX) 和阿达利穆马布 (ADL).
- 为指导临床医生在为儿科CD患者选择合适的生物药物.
主要方法:
- 在CD中对IFX和ADL的药理动力学数据的审查.
- 分析安全性,免疫性,患者偏好和合规性.
- 将成年CD治疗数据推断到儿科患者群体.
主要成果:
- 由于药理动力学,IFX在高炎症负担期间可能比ADL更有利.
- 预计ADL在维持缓解方面比IFX更有利.
- 安全性,免疫性,偏好和遵守是选择治疗的关键因素.
结论:
- 在儿科CD中选择抗TNF剂需要仔细评估临床指示和疾病行为.
- 诱导和维护的有效性,安全性,免疫性,患者偏好和合规性是关键考虑因素.
- 个性化治疗策略对于优化儿科CD的结果至关重要.
更多相关视频
08:26Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
Published on: June 14, 2018
10:35Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
Published on: December 26, 2017
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Drugs for Treatment of Ulcerative Colitis in IBD
